Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury

Summary

Antithrombin (AT) is a protein of the serpin superfamily involved in regulation of the proteolytic activity of the serine proteases of the coagulation system. AT is known to exhibit anti-inflammatory and cardioprotective properties when it binds to heparan sulfate proteo - glycans (HSPGs) on vascular cells. AMP-activated protein kinase (AMPK) plays an important cardioprotective role during myocardial ischaemia and reperfusion (I/R). To determine whether the cardioprotective signaling function of AT is mediated through the AMPK pathway, we evaluated the cardioprotective activities of wild-type AT and its two derivatives, one having high affinity and the other no affinity for heparin, in an acute I/R injury model in C57BL/6J mice in which the left anterior descending coronary artery was occluded. The serpin derivatives were given 5 minutes before reperfusion. The results showed that AT-WT can activate AMPK in both in vivo and ex vivo conditions. Blocking AMPK activity abolished the cardioprotective function of AT against I/R injury. The AT derivative having high affinity for heparin was more effective in activating AMPK and in limiting infraction, but the derivative lacking affinity for heparin was inactive in eliciting AMPK-dependent cardioprotective activity. Activation of AMPK by AT inhibited the inflammatory c-Jun N-terminal protein kinase (JNK) pathway during I/R. Further studies revealed that the AMPK activity induced by AT also modulates cardiac substrate metabolism by increasing glucose oxidation but inhibiting fatty acid oxidation during I/R. These results suggest that AT binds to HSPGs on heart tissues to invoke a cardioprotective function by triggering cardiac AMPK activation, thereby attenuating JNK inflammatory signalling pathways and modulating substrate metabolism during I/R.

• References

• 1 Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischaemia/reperfusion injury, preconditioning, and postcondi-tioning. Pharmacol Rev 2007; 59: 418-458.
• 2 Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003; 144: 5179-5183.
• 3 Dolinsky VW, Dyck JR. Role of AMP-activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol 2006; 291: H2557-2569.
• 4 Russell 3rd RR, Li J, Coven DL. et al. AMP-activated protein kinase mediates is-chaemic glucose uptake and prevents postischaemic cardiac dysfunction, apop-tosis, and injury. J Clin Invest 2004; 114: 495-503.
• 5 Ma H, Wang J, Thomas DP. et al. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischaemic recovery in the senescent heart. Circulation 2010; 122: 282-292.
• 6 Shibata R, Sato K, Pimentel DR. et al. Adiponectin protects against myocardial ischaemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 1096-1103.
• 7 Wang J, Yang L, Rezaie AR. et al. Activated protein C protects against myo-cardial ischaemic/reperfusion injury through AMP-activated protein kinase signalling. J Thromb Haemost 2011; 09: 1308-1317.
• 8 Morrison A, Yan X, Tong C. et al. Acute rosiglitazone treatment is cardioprotec-tive against ischaemia-reperfusion injury by modulating AMPK, Akt, and JNK signalling in nondiabetic mice. Am J Physiol Heart Circ Physiol 2011; 301: H895-902.
• 9 Wang J, Wang Y, Wang J. et al. Antithrombin is protective against myocardial is-chaemia and reperfusion injury. J Thromb Haemost 2013; 11: 1020-1028.
• 10 Schoots IG, Levi M, van Vliet AK. et al. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischaemia/rep-erfusion injury in rats. Crit Care Med 2004; 32: 1375-1383.
• 11 Esmon CT. Protein C anticoagulant pathway and its role in controlling micro-vascular thrombosis and inflammation. Crit Care Med 2001; 29: S48-51.
• 12 Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30: S325-331.
• 13 Irving JA, Pike RN, Lesk AM. et al. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-1864.
• 14 Olson ST, Swanson R, Raub-Segall E. et al. Accelerating ability of synthetic oli-gosaccharides on antithrombin inhibition of proteinases of the clotting and fi-brinolytic systems. Comparison with heparin and low-molecular-weight hepa-rin. Thromb Haemost 2004; 92: 929-939.
• 15 Shworak NW, Kobayashi T, de Agostini A. et al. Anticoagulant heparan sulfate to not clot--or not?. Prog Mol Biol Transl Sci 2010; 93: 153-178.
• 16 Jin L, Abrahams JP, Skinner R. et al. The anticoagulant activation of antithrom-bin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
• 17 Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-1737.
• 18 Bae JS, Rezaie AR. Mutagenesis studies toward understanding the intracellular signalling mechanism of antithrombin. J Thromb Haemost 2009; 07: 803-810.
• 19 Harada N, Okajima K, Kushimoto S. et al. Antithrombin reduces ischaemia/rep-erfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93: 157-164.
• 20 Hoffmann JN, Vollmar B, Inthorn D. et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279: C98-C107.
• 21 Ozden A, Sarioglu A, Demirkan NC. et al. Antithrombin III reduces renal is-chaemia-reperfusion injury in rats. Res Exp Med 2001; 200: 195-203.
• 22 Tong C, Morrison A, Yan X. et al. Macrophage migration inhibitory factor deficiency augments cardiac dysfunction in type 1 diabetic murine cardiomyocytes. J Diabetes 2010; 02: 267-274.
• 23 Makinde AO, Gamble J, Lopaschuk GD. Upregulation of 5‘-AMP-activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit. Circ Res 1997; 80: 482-489.
• 24 Amr Moussa JL. AMPK in myocardial infarction and diabetes: the yin/yang effect. Acta Pharmaceutica Sinica B 2012; 02: 10-20.
• 25 Morrison A, Li J. PPAR-gamma and AMPK--advantageous targets for myo-cardial ischaemia/reperfusion therapy. Biochem Pharmacol 2011; 82: 195-200.
• 26 Young LH, Li J, Baron SJ. et al. AMP-activated protein kinase: a key stress signalling pathway in the heart. Trends Cardiovasc Med 2005; 15: 110-118.
• 27 Costa R, Morrison A, Wang J. et al. Activated protein C modulates cardiac metabolism and augments autophagy in the ischaemic heart. J Thromb Haemost 2012; 10: 1736-1744.
• 28 Jefferson LS, Wolpert EB, Giger KE. et al. Regulation of protein synthesis in heart muscle. 3. Effect of anoxia on protein synthesis. J Biol Chem 1971; 246: 2171-2178.
• 29 Roach PJ. AMPK -> ULK1 -> autophagy. Mol Cell Biol 2011; 31: 3082-3084.
• 30 Kim AS, Miller EJ, Wright TM. et al. A small molecule AMPK activator protects the heart against ischaemia-reperfusion injury. J Mol Cell Cardiol 2011; 51: 24-32.
• 31 Schuksz M, Fuster MM, Brown JR. et al. Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci USA 2008; 105: 13075-13080.
• 32 Yang L, Manithody C, Qureshi SH. et al. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin. Thromb Haemost 2010; 103: 277-283.
• 33 McCoy AJ, Pei XY, Skinner R. et al. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol 2003; 326: 823-833.
• 34 Orsini F, Migliaccio E, Moroni M. et al. The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J Biol Chem 2004; 279: 25689-25695.
• 35 Giorgio M, Migliaccio E, Orsini F. et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005; 122: 221-233.
• 36 Pinton P, Rimessi A, Marchi S. et al. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 2007; 315: 659-663.
• 37 Egan DF, Shackelford DB, Mihaylova MM. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitop-hagy. Science 2011; 331: 456-461.
• 38 Kudo N, Barr AJ, Barr RL. et al. High rates of fatty acid oxidation during reper-fusion of ischaemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5‘-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995; 270: 17513-21750.
• 39 Russell 3rd RR, Bergeron R, Shulman GI. et al. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 1999; 277: H643-649.
• 40 Marsin AS, Bertrand L, Rider MH. et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischae-mia. Curr Biol 2000; 10: 1247-1255.
• 41 Kantor PF, Lucien A, Kozak R. et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-588.
• 42 McCormack JG, Barr RL, Wolff AA. et al. Ranolazine stimulates glucose oxidation in normoxic, ischaemic, and reperfused ischaemic rat hearts. Circulation 1996; 93: 135-142.